Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells

被引:30
作者
Narayan, Sharmal [1 ]
Choyce, Allison [1 ]
Linedale, Richard [1 ]
Saunders, Nicholas A. [1 ]
Dahler, Alison [1 ]
Chan, Emily [1 ]
Fernando, Germain J. [1 ]
Frazer, Ian H. [1 ]
Leggatt, Graham R. [1 ]
机构
[1] Univ Queensland, Diamantina Inst Canc Immunol & Metab Med, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Skin; Suppression; T cells; Thymus; Transgenic mice; CLASS-I MOLECULES; SELF-ANTIGEN; KERATIN-14; PROMOTER; NEGATIVE SELECTION; CENTRAL TOLERANCE; TRANSGENIC MICE; CERVICAL-CANCER; PEPTIDE; KERATINOCYTES; ONCOPROTEIN;
D O I
10.1002/eji.200838527
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The role of thymic versus peripheral epithelium in the regulation of the antigen-specific CD8 T-cell repertoire is still largely unresolved, We generated TCR-beta chain transgenic mice in which an increased frequency of peripheral CD8 T cells recognizes an epitope from a viral oncoprotein (HPV16E7) in the context of H-2D(b) MHC class I. When T cells from these mice developed through the thymus of mice expressing functional E7 protein from a keratin 14 promoter, no major perturbation to transgenic T-cell development in the thymus was observed in these double-transgenic mice. In contrast, peripheral CD8 T-cell responses in the single-transgenic, K14E7 mice, including those unrelated to E7 antigen, are reduced whereas CD4 T-cell responses and antibody production are unchanged in these mice. Peripheral non-responsiveness among CD8 T cells was mediated largely by CD4(+)CD25(+) T cells. This suggested that epithelium expressing HPV16E7 protein induces Treg that specifically down-regulate CD8 T-cell responses in the periphery. This may have important consequences for the treatment of cervical pre-cancers and provides a model for understanding differential suppression of T and B lymphocyte subsets by Treg.
引用
收藏
页码:481 / 490
页数:10
相关论文
共 38 条
[1]   Prevention of toxic epidermal necrolysis by regulatory T cells [J].
Azukizawa, H ;
Sano, S ;
Kosaka, H ;
Sumikawa, Y ;
Itami, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (06) :1722-1730
[2]   Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes [J].
Azukizawa, H ;
Kosaka, H ;
Sano, S ;
Heath, WR ;
Takahashi, I ;
Gao, XH ;
Sumikawa, Y ;
Okabe, M ;
Yoshikawa, K ;
Itami, S .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (07) :1879-1888
[3]   The timing of TCRα expression critically influences T cell development and selection [J].
Baldwin, TA ;
Sandau, MM ;
Jameson, SC ;
Hogquist, KA .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (01) :111-121
[4]   Dynamics of thymocyte-stromal cell interactions visualized by two-photon microscopy [J].
Bousso, P ;
Bhakta, NR ;
Lewis, RS ;
Robey, E .
SCIENCE, 2002, 296 (5574) :1876-1880
[5]   Dissociation of thymic positive and negative selection in transgenic mice expressing major histocompatibility complex class I molecules exclusively on thymic cortical epithelial cells [J].
Capone, M ;
Romagnoli, P ;
Beermann, F ;
MacDonald, HR ;
van Meerwijk, JPM .
BLOOD, 2001, 97 (05) :1336-1342
[6]   Human papillomavirus type 16 E7 oncoprotein expressed in peripheral epithelium tolerizes E7-directed cytotoxic T-lymphocyte precursors restricted through human (and mouse) major histocompatibility complex class I alleles [J].
Doan, T ;
Herd, K ;
Street, M ;
Bryson, G ;
Fernando, G ;
Lambert, P ;
Tindle, R .
JOURNAL OF VIROLOGY, 1999, 73 (07) :6166-6170
[7]  
Doan T, 2000, CANCER RES, V60, P2810
[8]   VACCINATION WITH CYTOTOXIC T-LYMPHOCYTE EPITOPE-CONTAINING PEPTIDE PROTECTS AGAINST A TUMOR-INDUCED BY HUMAN PAPILLOMAVIRUS TYPE-16-TRANSFORMED CELLS [J].
FELTKAMP, MCW ;
SMITS, HL ;
VIERBOOM, MPM ;
MINNAAR, RP ;
DEJONGH, BM ;
DRIJFHOUT, JW ;
TERSCHEGGET, J ;
MELIEF, CJM ;
KAST, WM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1993, 23 (09) :2242-2249
[9]  
Fernando GJP, 1998, SCAND J IMMUNOL, V47, P459
[10]  
Frazer IH, 1998, EUR J IMMUNOL, V28, P2791, DOI 10.1002/(SICI)1521-4141(199809)28:09<2791::AID-IMMU2791>3.0.CO